<DOC>
	<DOCNO>NCT01641926</DOCNO>
	<brief_summary>This study do compare safety efficacy PEG-Intron™ PEGASYS™ participant chronic hepatitis B ( hepatitis B envelope antigen [ HBeAg ] positive negative ) previously treat interferon .</brief_summary>
	<brief_title>A Study Safety Efficacy Pegylated Inferferon Alfa-2b ( PEG-Intron™ ) Versus Pegylated Interferon Alfa-2a ( PEGASYS™ ) Participants With Chronic Hepatitis B ( P08450 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Must able adhere dose visit schedule ≥ 40 kg Hepatitis B surface antigen ( HBsAg ) positive least 6 month AntiHBs negative Female participant childbearing potential must agree use acceptable method contraception least 2 week prior Day 1 continue least 1 month last dose study drug Inclusion Criteria HBeAg ( + ) participant : HBeAg ( + ) AntiHBe ( ) Inclusion Criteria HBeAg ( ) participant : HBeAg ( ) AntiHBe ( + ) Coinfection human immunodeficiency virus ( HIV ) hepatitis C hepatitis D virus Prior treatment interferon hepatitis B Use nucleoside/nucleotide analogue within 6 month screen visit time study Use investigational drug within 30 day screen visit Prior treatment herbal remedy know hepatotoxicity . All herbal remedy use hepatitis B treatment must discontinue Day 1 Evidence decompensated liver disease include , limited , history presence clinical ascites , bleed varix , hepatic encephalopathy Diabetic and/or hypertensive clinically significant ocular examination finding History stroke transient ischemic attack Immunologically mediate disease ( e.g. , inflammatory bowel disease [ Crohn 's disease , ulcerative colitis ] , celiac disease , rheumatoid arthritis , idiopathic thrombocytopenic purpura , systemic lupus erythematosus , autoimmune hemolytic anemia , scleroderma , sarcoidosis , severe psoriasis require oral inject treatment , symptomatic thyroid disorder ) Chronic pulmonary disease ( e.g. , chronic obstructive pulmonary disease , interstitial lung disease , pulmonary fibrosis , sarcoidosis ) Current history clinically significant cardiac abnormalities/dysfunction Any medical condition requiring , likely require , chronic systemic administration corticosteroid course trial Myelodysplastic syndrome Organ transplant ( include hematopoietic stem cell transplant ) cornea hair Pregnant nursing , intend become pregnant trial period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>